• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 18, 2015

View Archived Issues

Aveo Oncology lands $326M Novartis deal; extends cash runway for tivozanib

Aveo Oncology Inc. is getting $15 million up front in a potential $326 million deal with Novartis AG that hands over development and commercialization rights to preclinical-stage growth differentiation factor 15 (GDF15)-targeting antibody AV-380. Read More

In the clinic

Biolinerx Ltd., of Tel Aviv, Israel, initiated a phase IIb trial of BL-8040 as a consolidation treatment for acute myeloid leukemia (AML). The study will examine BL-8040 as part of a second stage treatment to improve outcomes for AML patients who achieved remission following induction therapy. Read More

Stock movers

Read More

Other news to note

Chiasma Inc., of Newton, Mass., reported that the FDA has accepted its new drug application for oral octreotide, a drug proposed for the maintenance therapy of adult patients with acromegaly. Read More

CRS: Something's got to give on pricing of specialty drugs

With specialty drugs taking an ever bigger bite of the U.S. prescription drug spend, pressure is mounting for more controls on pricing. Read More

Lack of regulation, legal protection main barriers for Bolivia's biotech sector

BOGOTA, Colombia – Most Latin American countries are developing new regulations and guidelines in an effort to facilitate the use of novel drugs and biosimilars in their health care systems. Bolivia, with a political regime in transition, stands as an exception in the region. Read More

Genentech paves path to anti-PDL1 filing with pivotal NSCLC study

Genentech Inc.'s most advanced immunotherapy candidate, atezolizumab, met its primary endpoint in a pivotal phase II study, shrinking tumors in people with locally advanced or metastatic non-small-cell lung cancer (NSCLC) whose disease expressed programmed cell death ligand-1 (PD-L1), and setting the stage for an early 2016 registration filing. Read More

Wuxi accepts $3.3B deal to go private, plans to leaves NYSE

SHANGHAI – Acting on an offer first announced in April, Shanghai-based Wuxi Pharmatech Inc.'s board of directors has accepted a $3.3 billion privatization bid, effectively taking China's largest CRO off the NYSE. Read More

GITR antibody-mediated cancer immunotherapies mechanism described

HONG KONG — The discovery that a novel mechanism of CD4+ T helper (Th) cell differentiation is mediated by co-stimulation of glucocorticoid-induced tumor necrosis factor receptor- (TNFR)-related protein (GITR) explains the mechanism of action of GITR-mediated cancer immunotherapies and warrants clinical trials of GITR agonists, a Korean study has found. Read More

Summit's oral DMD drug meets endpoint, moves to phase II

LONDON – Summit Therapeutics plc finally has cracked the problem of delivering SMT C1100, a universal treatment for Duchenne muscular dystrophy (DMD), opening the way for phase II development to start later this year. Read More

Financings

Edge Therapeutics Inc., of Berkeley Heights, N.J., filed an S-1 statement with the SEC seeking to raise up to $115 million, including overallotments, in an IPO. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe